Core Viewpoint - The company is leveraging its resource platform to connect with overseas partners and enhance its international hospital services, aiming to provide high-quality healthcare services to both domestic and international patients, particularly those in sub-health conditions [1] Group 1 - The company has been actively engaging with overseas partners to maximize its resources [1] - The company is focusing on providing quality healthcare services to both domestic and international patients [1] - The proportion of foreign patients in the company's medical institutions is currently small but is showing a year-on-year increasing trend [1]

Core Viewpoint - International Medical (000516.SZ) has clarified that its medical institutions do not currently engage in organ transplantation or gene therapy [1] Company Summary - The company operates medical institutions that are not involved in organ transplantation [1] - The company also does not participate in gene therapy activities [1] Industry Summary - The statement reflects the company's positioning within the healthcare industry, specifically in relation to advanced medical procedures such as organ transplantation and gene therapy [1]

国际医学在互动平台表示，公司旗下医疗机构暂不涉及器官移植和基因治疗。 （文章来源：第一财经） ...

证券之星消息，截至2026年1月28日收盘，国际医学(000516)报收于4.99元，下跌1.58%，换手率 2.17%，成交量47.81万手，成交额2.39亿元。 国际医学2025年三季报显示，前三季度公司主营收入29.95亿元，同比下降16.94%；归母净利润-2.94亿 元，同比下降38.45%；扣非净利润-3.12亿元，同比下降41.94%；其中2025年第三季度，公司单季度主 营收入9.61亿元，同比下降18.95%；单季度归母净利润-1.29亿元，同比下降234.24%；单季度扣非净利 润-1.23亿元，同比下降52.03%；负债率68.8%，投资收益2075.86万元，财务费用1.11亿元，毛利率 6.59%。国际医学（000516）主营业务：大健康医疗服务和现代医学技术转化应用。 1月28日的资金流向数据方面，主力资金净流出3864.74万元，占总成交额16.15%，游资资金净流出 149.37万元，占总成交额0.62%，散户资金净流入4014.11万元，占总成交额16.78%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 该股最近90天内共有2家机构给出评级，增持评级2家；过 ...

证券日报网讯 1月27日，国际医学（000516）在互动平台回答投资者提问时表示，公司2025年三季报 中，借款总额的变动与现金流量表相关筹资活动数据不同，主要原因是：公司下属子公司在向供应商支 付货款时，采用了国内信用证结算方式。该支付方式在资产负债表上列报为短期借款，但实际并未产生 相应的现金流入，在现金流量表的筹资活动部分不体现为借款收到的现金，因此账面借款减少金额与现 金流量表反映的偿还净额之间存在不同。 ...

证券之星消息，截至2026年1月27日收盘，国际医学(000516)报收于5.07元，下跌1.74%，换手率 3.31%，成交量73.0万手，成交额3.65亿元。 1月27日的资金流向数据方面，主力资金净流出2808.11万元，占总成交额7.7%，游资资金净流出 2325.61万元，占总成交额6.37%，散户资金净流入5133.71万元，占总成交额14.07%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 国际医学2025年三季报显示，前三季度公司主营收入29.95亿元，同比下降16.94%；归母净利润-2.94亿 元，同比下降38.45%；扣非净利润-3.12亿元，同比下降41.94%；其中2025年第三季度，公司单季度主 营收入9.61亿元，同比下降18.95%；单季度归母净利润-1.29亿元，同比下降234.24%；单季度扣非净利 润-1.23亿元，同比下降52.03%；负债率68.8%，投资收益2075.86万元，财务费用1.11亿元，毛利率 6.59%。国际医学（000516）主营业务：大健康医疗服务和现代医学技术转化应用。 该股最近90天内共有2家机构给出评级，增持评级2家；过去9 ...

Group 1 - The company expects a negative net profit for the fiscal year 2025, covering the period from January 1, 2025, to December 31, 2025 [1] - The company has communicated with its auditing firm regarding the performance forecast, and there are no discrepancies between the two parties [1] - The decline in operating income is attributed to market fluctuations and reforms in the DRG payment policy, leading to a decrease in revenue compared to the previous year [1] Group 2 - The company is implementing measures to adjust its business structure and improve operational efficiency, which has resulted in a narrowing of losses in the fourth quarter [1] - Despite these efforts, the total scale of operating income has not yet covered operational costs and period expenses [1]

3.业绩预告情况表 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000516 证券简称：国际医学 公告编号：2026-004 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、本期业绩预计情况 1.业绩预告期间：2025年1月1日至2025年12月31日 2.业绩预告情况：预计净利润为负值 本次业绩预告是公司财务部门进行初步测算后的预计，未经审计机构审计。具体财务数据将在公司2025 年度报告中详细披露。敬请广大投资者注意投资风险。 特此公告。 西安国际医学投资股份有限公司董事会 二〇二六年一月二十七日 二、与会计师事务所沟通情况 本次业绩预告未经注册会计师预审计。公司就本次业绩预告与为公司提供年度审计服务的会计师事务所 签字注册会计师进行了预沟通，双方在本次业绩预告方面不存在分歧。 三、业绩变动原因说明 报告期内，公司受市场波动、DRG支付政策改革等行业动态调整影响，营业收入同比下降。公司采取 调整业务结构，实施降本增效等措施并持续改善经营成效，第四季度亏损幅度收窄，但营业收入总规模 尚未能覆盖运营成本和期间费用。 四、风险提示 ...

Group 1 - The core viewpoint of the article indicates that International Medical (000516) is expecting significant losses in its financial performance for the year 2025, with projected net losses widening compared to the previous year [1][3] Group 2 - As of January 26, 2026, International Medical's stock closed at 5.16 yuan, down 0.96%, with a turnover rate of 3.28%, trading volume of 722,700 shares, and a transaction amount of 373 million yuan [1] - On January 26, the net inflow of main funds was 1.6254 million yuan, while retail investors showed a net inflow of 5.3559 million yuan, indicating mixed investor sentiment [1][3] Group 3 - The company forecasts a net profit loss attributable to shareholders of 295 million to 315 million yuan for 2025, which is an increase in losses compared to the previous year's loss of 254.1285 million yuan [1][3] - The expected operating revenue for 2025 is projected to be between 4.06 billion and 4.08 billion yuan, a decline from the previous year's revenue of 4.8154668 billion yuan, primarily due to market fluctuations and changes in DRG payment policies [1][3]

格隆汇1月26日丨国际医学(000516.SZ)在投资者互动平台表示，公司目前与阿里巴巴暂不涉及AI诊断方 面的合作。 ...